China Strong efficacy data attracts collaborators, but confidence shaken by other companies’ weaker results holds the whole field back Regend Therapeutics was founded in 2015 by Dr Ting Zhang and her husband, Professor Wei Zuo, to move stem cell research out of the lab and into patients. The company went on…
Europe The 2024 combination of 3P Biopharmaceuticals and Biovian gives 3PBIOVIAN greater scale and a broader technology base as Dámaso Molero Sánchez looks towards the CDMO’s next phase of growth. He sets out the rationale behind investments in microbial, mammalian and advanced-therapy manufacturing, explains why the US is becoming central to…
USA Innovators should hold CDMOs to a high bar, and CDMOs need to step up Syed T. Husain, Chairman & CEO of Made Scientific, outlines the organization’s differentiated strategy to disrupt cell therapy manufacturing through a focused, scalable CDMO model. He highlights the company’s Princeton facility, flexible client partnerships, workforce development…
Germany The biggest opportunity is to dare more, invest in promising ideas and become better at translating our excellent science into successful businesses Germany has no shortage of scientific expertise, but turning that research into companies, clinical programmes and ultimately medicines remains a persistent challenge. From its Berlin base, ProBioGen sits…
China Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman and CEO/CSO Dr Lei Fang explains how two decades of T-cell research underpin a differentiated pipeline, a China-first global development…
China CirCode Biomed is emerging at the forefront of a small but fast-evolving field seeking to turn circular RNA into a new class of medicines. From its roots in pioneering academic research, the Chinese biotech has moved circRNA into the clinic while building a diversified pipeline across ischaemic disease, in vivo…
USA Innovation cannot stop at the laboratory door. It must extend to how therapies are developed, approved, and reimbursed Brian Campbell, Vice President and General Manager of the US for Orchard Therapeutics, A Kyowa Kirin Company, discusses the critical role of newborn screening in identifying patients with metachromatic leukodystrophy (MLD), a…
Germany We need to bring together expertise in medicine, bioengineering, production technology and artificial intelligence Germany has the scientific expertise and clinical infrastructure to lead in cell and gene therapy, yet turning that strength into therapies that reach patients quickly and at scale remains a critical challenge. Dr Ulrike Köhl examines…
Germany The opportunity is not simply to replicate the US model, but to understand what works in each system and build on the strengths we already have in Europe After almost three decades in the US, Prof. Maike Sander returned to Germany with first-hand experience of an ecosystem where scientific discovery,…
Korea What I want, more than anything, is to introduce this modality to patients as quickly and as properly as possible Jaejin Cho, CEO of CellinCells, explains how the company’s proprietary Tissue Reforming Technology Platform (TRTP) translates developmental biology and quantitative tissue design into scaffold-free therapeutic tissue modules. He discusses the…
Korea Yoo Jong-man, CEO of Organoid Sciences discusses the company’s pioneering work in organoid-based regenerative medicine, drug evaluation, and precision medicine. He highlights its regulatory achievements, proprietary technology platforms, global expansion, and Phase I clinical programme for refractory Crohn’s disease. Looking ahead, he aims to establish Organoid Sciences as a global…
Europe Childhood cancer survival rates in high-income countries now exceed 80 percent, but that masks a more uneven picture: paediatric drug development lags far behind adult oncology, follow-up and psychosocial care remain patchy across Europe, and survivors can face life-altering side effects that surface decades after treatment ends. Carina Schneider and…
See our Cookie Privacy Policy Here
